Nothing Special   »   [go: up one dir, main page]

MX2023010206A - Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario. - Google Patents

Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.

Info

Publication number
MX2023010206A
MX2023010206A MX2023010206A MX2023010206A MX2023010206A MX 2023010206 A MX2023010206 A MX 2023010206A MX 2023010206 A MX2023010206 A MX 2023010206A MX 2023010206 A MX2023010206 A MX 2023010206A MX 2023010206 A MX2023010206 A MX 2023010206A
Authority
MX
Mexico
Prior art keywords
plasma kallikrein
hereditary angioedema
kallikrein inhibitors
angioedema attack
preventing hereditary
Prior art date
Application number
MX2023010206A
Other languages
English (en)
Inventor
Yung Chyung
Burt Adelman
Daniel J Sexton
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57005262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023010206(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2023010206A publication Critical patent/MX2023010206A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

En este documento se proporcionan anticuerpos calicreína de union a la calicreina plasmática activa y métodos de uso de tales anticuerpos en la prevención del ataque de angioedema hereditario o la reducción de la tasa del ataque del angioedema hereditario.
MX2023010206A 2015-03-30 2017-09-27 Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario. MX2023010206A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562140289P 2015-03-30 2015-03-30
US201562140277P 2015-03-30 2015-03-30
US201562214293P 2015-09-04 2015-09-04

Publications (1)

Publication Number Publication Date
MX2023010206A true MX2023010206A (es) 2023-09-11

Family

ID=57005262

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012423A MX2017012423A (es) 2015-03-30 2016-03-30 Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.
MX2023010206A MX2023010206A (es) 2015-03-30 2017-09-27 Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017012423A MX2017012423A (es) 2015-03-30 2016-03-30 Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.

Country Status (14)

Country Link
US (2) US20180298110A1 (es)
EP (2) EP3916020A1 (es)
JP (3) JP7008920B2 (es)
KR (2) KR20230164767A (es)
CN (1) CN107614532A (es)
AU (2) AU2016243160B2 (es)
BR (1) BR112017020864A2 (es)
CA (1) CA2979713A1 (es)
CO (1) CO2017009404A2 (es)
EA (1) EA201792161A1 (es)
HK (1) HK1250995A1 (es)
IL (2) IL305207A (es)
MX (2) MX2017012423A (es)
WO (1) WO2016160926A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2521568B1 (en) 2010-01-06 2018-07-25 Dyax Corp. Plasma kallikrein binding proteins
US8816055B2 (en) 2011-01-06 2014-08-26 Dyax Corp. Plasma kallikrein binding proteins
CN105051068A (zh) 2013-03-15 2015-11-11 戴埃克斯有限公司 抗血浆激肽释放酶抗体
KR20240033156A (ko) 2014-01-21 2024-03-12 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
JP6719384B2 (ja) 2014-03-27 2020-07-15 ダイアックス コーポレーション 糖尿病黄斑浮腫の治療のための組成物および方法
KR20180094028A (ko) 2015-12-11 2018-08-22 다이액스 코포레이션 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
MX2019002918A (es) * 2016-09-16 2019-07-18 Dyax Corp Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
CA3070717A1 (en) * 2017-08-04 2019-02-07 Dyax Corp. Inhibitors of plasma kallikrein and uses thereof
CN112770751A (zh) * 2018-02-28 2021-05-07 爱顿制药公司 遗传性血管性水肿的治疗
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
CA3110689A1 (en) * 2018-08-30 2020-03-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN114166924A (zh) * 2021-12-03 2022-03-11 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ATE275583T1 (de) 1994-01-11 2004-09-15 Dyax Corp KALLIKREINHEMMENDE ßKUNITZ-DOMÄNEß-PROTEINE UND DERIVATEN DAVON
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
PT1531791E (pt) 2002-06-07 2010-12-16 Dyax Corp Prevenção e redução da isquémia
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP2521568B1 (en) * 2010-01-06 2018-07-25 Dyax Corp. Plasma kallikrein binding proteins
US8816055B2 (en) * 2011-01-06 2014-08-26 Dyax Corp. Plasma kallikrein binding proteins
EP4438625A2 (en) * 2011-05-02 2024-10-02 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US11156612B2 (en) * 2013-01-20 2021-10-26 Takeda Pharmaceutical Company Limited Methods of determining levels of cleaved and/or intact kininogen
CN105051068A (zh) * 2013-03-15 2015-11-11 戴埃克斯有限公司 抗血浆激肽释放酶抗体
KR20140119396A (ko) * 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
EP3808857A1 (en) * 2013-10-21 2021-04-21 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
KR20240033156A (ko) * 2014-01-21 2024-03-12 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도

Also Published As

Publication number Publication date
WO2016160926A1 (en) 2016-10-06
NZ735659A (en) 2023-08-25
US20220169749A1 (en) 2022-06-02
AU2016243160B2 (en) 2022-02-24
MX2017012423A (es) 2018-01-26
EA201792161A1 (ru) 2018-04-30
KR20170135885A (ko) 2017-12-08
CA2979713A1 (en) 2016-10-06
KR20230164767A (ko) 2023-12-04
EP3286226A1 (en) 2018-02-28
EP3916020A1 (en) 2021-12-01
JP7309836B2 (ja) 2023-07-18
NZ774543A (en) 2024-04-26
IL254292A0 (en) 2017-10-31
AU2016243160A1 (en) 2017-10-05
AU2022203180A1 (en) 2022-06-02
JP7008920B2 (ja) 2022-01-25
CO2017009404A2 (es) 2018-03-09
HK1250995A1 (zh) 2019-01-18
BR112017020864A2 (pt) 2018-07-10
CN107614532A (zh) 2018-01-19
IL305207A (en) 2023-10-01
US20180298110A1 (en) 2018-10-18
JP2018514510A (ja) 2018-06-07
EP3286226A4 (en) 2018-12-05
JP2023130442A (ja) 2023-09-20
JP2022037131A (ja) 2022-03-08
KR102607829B1 (ko) 2023-12-01

Similar Documents

Publication Publication Date Title
MX2023010206A (es) Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
MX2023013342A (es) Celulas que expresan el receptor de antigeno quimerico (car) con funcion o expresion de tet reducida y metodos de uso de las mismas.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
SG10201902326XA (en) Mk2 inhibitors and uses thereof
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
MX2015006478A (es) Inhibidores de glutaminasa y metodos de empleo.
PH12018501009A1 (en) Methods for treating conditions associated with masp-2 dependent complement activation
MX2021011946A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
IL259691A (en) Plasma kallikrein inhibitors and their uses for the treatment of hereditary angioedema attack
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
MX2021006326A (es) Inhibidores de pcna.
IL251880A0 (en) Preparations for the treatment of acute, post-operative or chronic pain and methods of using them
EP3426256A4 (en) METHOD OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND DISEASES ASSOCIATED WITH SGLT-2 INHIBITOR
MX2016009665A (es) Composiciones y metodos para el tratamiento de la hemorragia cerebral.
EP3223613A4 (en) 4-fluoro-thio-containing inhibitors of app2, compositions thereof and method of use
EP3377843A4 (en) SYSTEM AND METHOD FOR PANEL FAILURE